Improving the Quality of Adeno-Associated Viral Vector Preparations: The Challenge of Product-Related Impurities

Human Gene Therapy Methods

Volumn 28, Issue 3, 2017, Pages 101-108

  Schnödt, Maria ^a,b,c   Büning, Hildegard ^a,b,c,d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

AAV vectors; DNA impurities; Empty capsids; Vector characterization; Vector purification

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; VIRUS DNA;

DNA SEQUENCE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROKARYOTE; QUALITY CONTROL; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; DEPENDOPARVOVIRUS; DNA CONTAMINATION; GENE THERAPY; GENE VECTOR; GENETICS; PROCEDURES; STANDARDS;

ANIMALS; DEPENDOVIRUS; DNA CONTAMINATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS;

EID: 85021145144     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2016.188     Document Type: Review

References (85)

1. Zinn E, Vandenberghe LH. Adeno-associated virus: fit to serve. Curr Opin Virol 2014;8:90-97.
2. Gao G, Vandenberghe LH, Alvira MR, et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 2004;78:6381-6388.
3. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther 2012;20:699-708.
4. Srivastava A. In vivo tissue-tropism of adenoassociated viral vectors Curr Opin Virol 2016;21:75-80.
5. Hastie E, Samulski RJ. Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success-a personal perspective. Hum Gene Ther 2015;26:257-265.
6. Kotterman MA, Chalberg TW, Schaffer DV. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 2015;17:63-89.
7. Wright J. Product-related impurities in clinicalgrade recombinant AAV vectors: characterization and risk assessment Biomedicines 2014;2:80-97.
8. Carter BJ. Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol Ther 2004;10:981-989.
9. Rolling F, Samulski RJ. AAV as a viral vector for human gene therapy: generation of recombinant virus. Mol Biotechnol 1995;3:9-15.
10. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72: 2224-2232.
11. Matsushita T, Elliger S, Elliger C, et al. Adenoassociated virus vectors can be efficiently produced without helper virus. Gene Ther 1998;5: 938-945.
12. Grimm D, Kern A, Rittner K, et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 1998; 9:2745-2760.
13. Grieger JC, Soltys SM, Samulski RJ. Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Mol Ther 2016;24:287-297.
14. Ayuso E, Mingozzi F, Bosch F. Production, purification and characterization of adeno-associated vectors. Curr Gene Ther 2010;10:423-436.
15. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Gene Ther 2002;13:1935-1943.
16. Galibert L, Merten O-W. Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases. J Invertebr Pathol 2011;107(Suppl):S80-S93.
17. Mietzsch M, Grasse S, Zurawski C, et al. OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy. Hum Gene Ther 2014;25:212-222.
18. Clément N, Grieger JC. Manufacturing of recombinant adeno-associated viral vectors for clinical trials. Mol Ther Methods Clin Dev 2016;3:16002.
19. Vandenberghe LH, Xiao R, Lock M, et al. Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther 2010;21: 1251-1257.
20. Okada T, Nonaka-Sarukawa M, Uchibori R, et al. Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Hum Gene Ther 2009;20:1013-1021.
21. Lock M, Alvira M, Vandenberghe LH, et al. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 2010;21:1259-1271.
22. Piras BA, Drury JE, Morton CL, et al. Distribution of AAV8 particles in cell lysates and culture media changes with time and is dependent on the recombinant vector. Mol Ther Methods Clin Dev 2016;3:16015.
23. Benskey MJ, Sandoval IM, Manfredsson FP. Continuous collection of adeno-associated virus from producer cell medium significantly increases total viral yield. Hum Gene Ther Methods 2016;27: 32-45.
24. Allay JA, Sleep S, Long S, et al. Good manufacturing practice production of selfcomplementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther 2011;22:595-604.
25. Sommer J. Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther 2003;7:122-128.
26. Zeltner N, Kohlbrenner E, Clément N, et al. Nearperfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors. Gene Ther 2010;17:872-879.
27. Kapranov P, Chen L, Dederich D, et al. Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther 2012;23:46-55.
28. King JA, Dubielzig R, Grimm D, et al. DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 2001;20:3282-3291.
29. Bleker S, Sonntag F, Kleinschmidt JA. Mutational analysis of narrow pores at the fivefold symmetry axes of adeno-associated virus type 2 capsids reveals a dual role in genome packaging and activation of phospholipase A2 activity. J Virol 2005;79:2528-2540.
30. Samulski RJ, Muzyczka N. AAV-mediated gene therapy for research and therapeutic purposes. Annu Rev Virol 2014;1:427-451.
31. Ling C, Wang Y, Lu Y, et al. The adeno-associated virus genome packaging puzzle. J Mol Genet Med 2015;9(3).
32. Qu G, Bahr-Davidson J, Prado J, et al. Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anionexchange column chromatography. J Virol Methods 2007;140:183-192.
33. Mingozzi F, Anguela XM, Pavani G, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med 2013;5: 194ra92.
34. Hösel M, Broxtermann M, Janicki H, et al. Tolllike receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology 2012; 55:287-297.
35. Mingozzi F, Maus MV, Hui DJ, et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007;13:419-422.
36. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
37. Nathwani AC, Reiss UM, Tuddenham EGD, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371: 1994-2004.
38. Gao K, Li M, Zhong L, et al. Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side-effects. Mol Ther Methods Clin Dev 2014;1: 20139.
39. Grimm D, Kern A, Pawlita M, et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Ther 1999;6:1322-1330.
40. Kuck D, Kern A, Kleinschmidt JA. Development of AAV serotype-specific ELISAs using novel monoclonal antibodies. J Virol Methods 2007;140: 17-24.
41. Burnham B, Nass S, Kong E, et al. Analytical ultracentrifugation as an approach to characterize recombinant adeno-associated viral vectors. Hum Gene Ther Methods 2015;26:228-242.
42. Pierson EE, Keifer DZ, Asokan A, et al. Resolving adeno-associated viral particle diversity with charge detection mass spectrometry. Anal Chem 2016;88:6718-6725.
43. Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999;6:973-985.
44. Strobel B, Miller FD, Rist W, et al. Comparative analysis of cesium chloride-and iodixanol-based purification of recombinant adeno-associated virus (AAV) vectors for preclinical applications. Hum Gene Ther Methods 2015;26:147-157.
45. Ayuso E, Mingozzi F, Montane J, et al. High AAV vector purity results in serotype-and tissueindependent enhancement of transduction efficiency. Gene Ther 2010;17:503-510.
46. Fraser Wright J, Wellman J, High K. Manufacturing and regulatory strategies for clinical AAV2-hRPE65. Curr Gene Ther 2010;10:341-349.
47. Venkatakrishnan B, Yarbrough J, Domsic J, et al. Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol 2013;87:4974-4984.
48. Kaludov N, Handelman B, Chiorini JA. Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 2002;13:1235-1243.
49. Davidoff AM, Ng CYC, Sleep S, et al. Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J Virol Methods 2004;121:209-215.
50. Urabe M, Xin K-Q, Obara Y, et al. Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression. Mol Ther 2006;13:823-828.
51. Tomono T, Hirai Y, Okada H, et al. Ultracentrifugation-free chromatography-mediated large-scale purification of recombinant adenoassociated virus serotype 1 (rAAV1). Mol Ther Methods Clin Dev 2016;3:15058.
52. Allen JM, Debelak DJ, Reynolds TC, et al. Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol 1997;71:6816-6822.
53. Wang XS, Khuntirat B, Qing K, et al. Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination. J Virol 1998;72:5472-5480.
54. Im DS, Muzyczka N. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell 1990;61:447-457.
55. Im DS, Muzyczka N. Partial purification of adenoassociated virus Rep78, Rep52, and Rep40 and their biochemical characterization. J Virol 1992; 66:1119-1128.
56. Halbert CL, Metzger MJ, Lam S-L, et al. Capsidexpressing DNA in AAV vectors and its elimination by use of an oversize capsid gene for vector production. Gene Ther 2011;18:411-417.
57. Clark KR, Liu X, McGrath JP, et al. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 1999;10: 1031-1039.
58. Cao L, Liu Y, During MJ, et al. High-titer, wildtype free recombinant adeno-associated virus vector production using intron-containing helper plasmids. J Virol 2000;74:11456-11463.
59. Li C, Samulski RJ. Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production. Virology 2005;335: 10-21.
60. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989;63:3822-3828.
61. Emmerling VV, Pegel A, Milian EG, et al. Rational plasmid design and bioprocess optimization to enhance recombinant adeno-associated virus (AAV) productivity in mammalian cells. Biotechnol J 2016;11:290-297.
62. Lu H, Qu G, Yang X, et al. Systemic elimination of de novo capsid protein synthesis from replicationcompetent AAV contamination in the liver. Hum Gene Ther 2011;22:625-632.
63. Gao GP, Qu G, Faust LZ, et al. High-titer adenoassociated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998;9: 2353-2362.
64. Dong B, Moore AR, Dai J, et al. A concept of eliminating nonhomologous recombination for scalable and safe AAV vector generation for human gene therapy. Nucleic Acids Res 2013;41: 6609-6617.
65. Chadeuf G, Ciron C, Moullier P, et al. Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol Ther 2005;12:744-753.
66. Lecomte E, Tournaire B, Cogné B, et al. Advanced characterization of DNA molecules in rAAV vector preparations by single-stranded virus nextgeneration sequencing. Mol Ther Nucleic Acids 2015;4:e260.
67. Hauck B, Murphy SL, Smith PH, et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther 2009;17:144-152.
68. Schnödt M, Schmeer M, Kracher B, et al. DNA minicircle technology improves purity of adenoassociated viral vector preparations. Mol Ther Nucleic Acids 2016;5:e355.
69. Bauer S, Kirschning CJ, Häcker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001;98:9237-9242.
70. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008;26:549-551.
71. Chen ZY, He CY, Meuse L, et al. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther 2004;11: 856-864.
72. Tan Y, Li S, Pitt BR, et al. The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. Hum Gene Ther 1999;10:2153-2161.
73. Miller DG, Rutledge EA, Russell DW. Chromosomal effects of adeno-associated virus vector integration. Nat Genet 2002;30:147-148.
74. Grieger JC, Samulski RJ. Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps. J Virol 2005;79:9933-9944.
75. Hirsch ML, Wolf SJ, Samulski RJ. Delivering transgenic DNA exceeding the carrying capacity of AAV vectors. Methods Mol Biol 2016;1382: 21-39.
76. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adenoassociated virus. Hum Gene Ther 1996;7:2101-2112.
77. McCarty DM. Self-complementary AAV vectors: advances and applications. Mol Ther 2008;16: 1648-1656.
78. McCarty DM, Monahan PE, Samulski RJ. Selfcomplementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 2001;8:1248-1254.
79. Lock M, McGorray S, Auricchio A, et al. Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther 2010;21:1273-1285.
80. Ayuso E, Blouin V, Lock M, et al. Manufacturing and characterization of a recombinant adenoassociated virus type 8 reference standard material. Hum Gene Ther 2014;25:977-987.
81. Rabinowitz JE, Rolling F, Li C, et al. Crosspackaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002;76:791-801.
82. Grimm D, Pandey K, Nakai H, et al. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 2006;80:426-439.
83. Zhou X, Gao G, Owens RA, et al. 404. Roles of inverted terminal repeats (ITRs) and capsid proteins from novel NHP AAVs in rAAV mediated gene transfer. Mol Ther 2005;11(Suppl 1):S156.
84. Ling C, Yin Z, Li J, et al. Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors. Mol Ther Methods Clin Dev 2016;3: 16029.
85. Drouin LM, Lins B, Janssen M, et al. Cryoelectron microscopy reconstruction and stability studies of wild-type and R432A variant of AAV2 reveals capsid structural stability is a major factor in genome packaging. J Virol 2016;90: 8542-8551.